Inflammasomes: potential therapeutic targets in atherosclerotic cardiovascular disease
Inflammasomes: potential therapeutic targets in atherosclerotic cardiovascular disease
复制标题
炎症小体：动脉粥样硬化性心血管疾病的潜在治疗靶点
DOI：
10.2174/1871530322666220407090916
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Ru Zhang
中科院分区：
文献类型：
--
作者：
Ping Wang;Jun Ma;Ru Zhang
摘要：最近的研究表明，白细胞介素1β单克隆抗体改善冠心病患者的预后与血脂水平无关，首次为动脉粥样硬化性疾病抗炎治疗的有效性提供了证据。然而，单独使用白细胞介素1β单克隆抗体治疗仍然存在显著的残留炎症风险。炎性小体是由模式识别受体和其他炎性分子组成的细胞内蛋白复合物，其激活是炎症反应发展的关键步骤，靶向炎性小体以减少残余炎症已成为动脉粥样硬化疾病抗炎治疗的新思路。本文综述了炎性小体在动脉粥样硬化疾病中的作用和机制，并列举了目前认为有可能通过抗炎小体治疗动脉粥样硬化的药物，以期为开发新的抗炎治疗方法预防和治疗动脉粥样硬化疾病提供参考。
Abstract:.Recent studies have shown that interleukin 1β monoclonal antibody improves the prognosis of patients with coronary artery disease independently of lipid levels, providing the first evidence of the effectiveness of anti-inflammatory treatment for atherosclerotic disease. However, there is still a significant risk of residual inflammation with interleukin 1β monoclonal antibody therapy alone. Activation of the inflammasome, an intracellular protein complex composed of pattern recognition receptors and other inflammatory molecules, is a critical step in the development of the inflammatory response, and targeting the inflammasome to reduce residual inflammation has emerged as a new idea in the anti-inflammatory treatment of atherosclerotic disease. This review discusses the role and mechanisms of inflammasomes in atherosclerotic disease and lists drugs that are currently thought to potentially treat atherosclerosis through anti-inflammasomes, hoping to provide insight into the development of new anti-inflammatory therapies for the prevention and treatment of atherosclerotic disease.